NMTC reports a GAAP EPS loss of $0.28 and $2M revenue, both missing analyst expectations by $0.06 and $0.55M respectively.
NeuroOne Medical Technologies reported a third-quarter GAAP loss per share of $0.28, missing estimates by $0.06. Revenue reached $2 million, up 17.6% year-over-year but falling short of projections by $0.55 million.
The company’s cash reserves declined to $2.0 million as of June 30, 2026, down from $6.6 million at the end of September 2025. Analysts had anticipated narrower losses and higher revenue for the period.
No immediate market reaction was disclosed in the release.